ホーム>>m7(3'OMeG)(5')ppp(5')(2'OMeA)pG

m7(3'OMeG)(5')ppp(5')(2'OMeA)pG

カタログ番号GN20152

m7(3'OMeG)(5')ppp(5')(2'OMeA)pG is a co-transcriptional capping reagent that can produce Cap 1 structure with a capping efficiency of up to 98%.

Products are for research use only. Not for human use. We do not sell to patients.

m7(3'OMeG)(5')ppp(5')(2'OMeA)pG 化学構造

サイズ 価格 在庫数 個数
1µmole
$363.00
在庫あり
5µmole
$1,586.00
在庫あり
10µmole
$3,194.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Description

m7(3'OMeG)(5')ppp(5')(2'OMeA)pG is a co-transcriptional capping reagent that can produce Cap 1 structure with a capping efficiency of up to 98%. m7(3'OMeG)(5')ppp(5')(2'OMeA)pG needs to be used with a specific 5' AG 3' start sequence.

Compared with Cap 0 structure (ARCA and mCap capping), mRNA with Cap 1 structure is more suitable for mammalian systems and has higher transcription and translation efficiency. It is often used in protein production, RNA therapy and vaccine research.

Product Details

purity >95.00% Extinction Coefficient 30,539 Lmol-1cm-1 at 255 nm
Formula C33H45N15O24P4 (free acid) M.Wt 1159.6
Salt Form Na+ 濃度 100 mM
Buffer H2O Storage -20°C or below
同義語 3'OMe-m7GpppAmpG Backbone 5'-5'-Triphosphate
Base Analog Adenosine, Guanosine Sugar Type
Nucleotide Category Cap analogs
応用 CRISPR, In vitro Transcription, Recombinases, TALENS, Transposases, Vaccine Development, Zinc Finger Nucleases

レビュー

Review for m7(3'OMeG)(5')ppp(5')(2'OMeA)pG

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for m7(3'OMeG)(5')ppp(5')(2'OMeA)pG

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.